Our core technologies lie in the organic synthesis of oligopeptides, amino acid derivatives, and heterocyclic compounds. Research and development of amino acid-based prodrugs and peptide-based drugs have been growing in decades. Modifications to amino acid side chains are often applied to enhance specificity, biological activity and proteolytic resistance. Utilizing Build, Couple & Pair (B/C/P) methodologies, we transform natural and unnatural amino acid building blocks into novel peptides and amino acid derivatives, at scales ranging from laboratory to kilo manufacturing.
Using an innovative Target-Directed Functional Group (TDFG) transformation platform, we transform natural and unnatural amino acid building blocks into derivatives that are essential for developing and modifying drug molecular entities in discovery and development stages. We, at CORUM, have more than 28 innovation patents, of which 17 patents are novel peptides and unnatural amino acids.
Corum is capable of synthesizing complex API and intermediates via a wide range of advanced chemical reactions.
Some drugs were developed and marketed as racemates. As technology advances, the regulatory authorities require drug developers to separate stereoisomers and evaluate their efficacies individually. Some stereoisomers exhibit different properties in various aspects such as toxicology and pharmacokinetics (absorption, distribution, mechanism and excretion). Differences in toxicity may result in adverse effects, which pose big challenges to the development of safe and effective drugs. With a proven track record of success, we develop chiral assay to separate and quantify individual stereoisomers so that the pharmacokinetic and toxicity profile of individual stereoisomers can be characterized.
Language